Straits Times Index
3,072.99 -11.71 (-0.38%) S&P 500
4,544.29 -6.29 (-0.14%) Dow
35,700.84 +270.42 (+0.76%) Nasdaq
14,168.23 -90.26 (-0.63%) Bitcoin USD
37,578.38 -260.48 (-0.69%) CMC Crypto 200
777.21 -6.43 (-0.82%)
Viatris Inc. (VTRS)
- Insider Monkey
Top 30 Lowest P/E Ratios of the S&P 500
In this article, we will take a look at the top 30 lowest P/E ratios of the S&P 500. To see more such companies, go directly to Top 5 Lowest P/E Ratios of the S&P 500. In its 2024 stock market outlook report, Goldman Sachs claimed that the hard part of the Fed’s battle against […]
- PR Newswire
Viatris to Participate in the Jefferies London Healthcare Conference
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jefferies London Healthcare Conference in London, UK on Wednesday, November 15, 2023. Chief Executive Officer Scott A. Smith, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula will represent the Company in a fireside chat scheduled at 4:30 a.m. ET / 9:30 a.m. GMT.
- PR Newswire
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive results from the YUPELRI® (revefenacin) Phase III placebo-controlled clinical trial conducted in China assessing the efficacy and safety of YUPELRI, a once-daily nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with COPD. Top-line results showed that YUPELRI met its primary efficacy endpoint demonstrating a statistically sign
